Itama Ranoraya PT
IDX:IRRA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (1.5), the stock would be worth Rp576.24 (46% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1 | Rp394 |
0%
|
| 3-Year Average | 1.5 | Rp576.24 |
+46%
|
| 5-Year Average | 1.7 | Rp645.03 |
+64%
|
| Industry Average | 3 | Rp1 147.45 |
+191%
|
| Country Average | 1.6 | Rp614.18 |
+56%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| ID |
I
|
Itama Ranoraya PT
IDX:IRRA
|
594.1B IDR | 1 | 9.1 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
101.9B USD | -79.4 | 23.8 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
60.4B USD | 31.7 | 37.2 | |
| US |
|
Cencora Inc
NYSE:COR
|
60.3B USD | 31.9 | 37.4 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
47.8B USD | -16.8 | 29.1 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
31.9B AUD | 6.4 | 34.6 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
61.9B CNY | 0.8 | 10.8 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
8.9B USD | 2.7 | 22.3 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
60B CNY | 2.5 | 21.2 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 6 | 89.6 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
57.7B HKD | 0.6 | 7.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.9 |
| Median | 1.6 |
| 70th Percentile | 2.9 |
| Max | 652 108.7 |
Other Multiples
Itama Ranoraya PT
Glance View
PT Itama Ranoraya Tbk operates as a medical devices distributor. The company is headquartered in Jakarta Timur, Dki Jakarta and currently employs 169 full-time employees. The company went IPO on 2019-10-15. The firm operates in the field of wholesale trading of laboratory equipment, pharmaceutical equipment, and medical devices for humans. The firm carries out its operations through four products, namely the non-electromedical sterile medical devices, in-vitro diagnostic, electromedical sterile medical devices, and other products. Its business segment focuses on in-vitro diagnostic (IVD), medical imaging, surgical instrument and disposable, critical care, blood banking and transfusion, cardiovascular, brain management, cancer, urology, and maternal and neonatal care. Its products include Oneject, Abbott, Terumo, Becton Dickinson (BD), HMD, Vestfrost, Balmed, iGene, AVIMAC, and HemoCue.
